Testing a new drug combo for newly diagnosed triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding an IL-1 inhibitor (isunakinra) to standard immunotherapy (pembrolizumab) and chemotherapy can help shrink tumors in newly diagnosed, advanced triple-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman over 18 with newly diagnosed, advanced triple-negative breast cancer that hasn't been treated yet.
- You need to provide at least 2 tumor samples from a biopsy.
- You must have a good performance status (ECOG 0 or 1), meaning you can carry out daily activities without help.
- Your organs (kidneys, liver, blood counts) must work well enough.
- If you could become pregnant, you must use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a JAK1 inhibitor (ivarmacitinib) can help treat triple-negative breast cancer that stopped responding to immunotherapy. It's for people with advanced or metastatic TNBC who have already tried and failed anti-PD-1/PD-L1 treatment.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Hear when a new Triple-Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.